# Safety and Immunogenicity Study of IP-QSV Vaccine in Healthy Adults/Adolescents, Children and Infants

> **NCT07666750** · PHASE1,PHASE2 · NOT_YET_RECRUITING · sponsor: **International Vaccine Institute** · enrollment: 370 (estimated)

## Conditions studied

- Shigella Infection

## Interventions

- **BIOLOGICAL:** 30μg IP-QSV
- **OTHER:** Placebo
- **BIOLOGICAL:** 10μg IP-QSV
- **BIOLOGICAL:** 2μg IP-QSV

## Key facts

- **NCT ID:** NCT07666750
- **Lead sponsor:** International Vaccine Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-07
- **Primary completion:** 2027-08
- **Final completion:** 2028-11
- **Target enrollment:** 370 (ESTIMATED)
- **Last updated:** 2026-06-24

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07666750

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07666750, "Safety and Immunogenicity Study of IP-QSV Vaccine in Healthy Adults/Adolescents, Children and Infants". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07666750. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*